Overall verdict
Sell
3.4/10
1-year performance
+207.57%
Score breakdown
Up 207.6% over 1 year, 49% of the 52-week range.
Strongest: Financial strength 5.8/10. Weakest: Shareholder return 0.0/10.
5 analysts, target +1.8% vs the price.
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases ;
and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
Brent Pfeiffenberger
Founded
2018
Employees
78
Revenue / employee
1.4M USD
Next earnings
November 9, 2026 (estimated)
Institutional holders
- RA CAPITAL MANAGEMENT, L.P.9.80%
- TCG Crossover Management, LLC9.80%
- Versant Venture Management, LLC6.72%
- Deep Track Capital, LP5.23%
- Venrock Adviser, LLC4.80%
- Commodore Capital LP4.80%
- RTW INVESTMENTS, LP4.80%
- BlackRock, Inc.4.47%
- VANGUARD CAPITAL MANAGEMENT LLC3.15%
- Other institutions33.68%
- Rest of the register12.74%
98 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
3.04 USD
52-week low
0.43 USD
1-year performance
207.57%
Rising
Year-to-date performance
76.30%
Rising
Drawdown
-43.75%
Major drawdown
Position in the 52-week range
49% of range
ROIC -41.9%, ROE -49.7%.
Net margin
—
Sector -223.82%|S&P 13.15%
Gross margin
—
Return on equity (ROE)
-49.65%
Negative
Sector -58.98%|S&P 16.61%
Return on invested capital (ROIC)
-41.95%
Negative
Free cash flow margin (FCF)
—
Revenue to net income
Growth
3.3/10Revenue down 100.0% over 1 year.
Revenue (trailing 12 months)
0 USD
Revenue growth (1y)
-100.00%
Declining
Revenue growth (3y)
1999.71%
Hyper-growth
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.4x|S&P 24.1x
Forward P/E (adjusted)
—
N/A (loss)
EV / EBITDA
—
N/A (loss)
Sector 14.4x|S&P 15.2x
PEG
—
Sector -0.03|S&P 0.90
Market cap
310M USD
Financial strength
5.8/10Cash covers 309.6% of the debt, no net debt (net cash).
Net debt / EBITDA
—
Gearing (net debt / equity)
-34.88%
Net cash
Cash
120M USD
Cash / market cap
38.66%
Very solid
Cash / total debt
309.61%
Net cash
Interest coverage
-72.2x
Stretched
Net debt
-81.0M USD
Equity
232M USD
Closed daily candles, 2 years
Last close on October 21, 2026: 1.61 USD
- MM201.52
- MM501.81
- MM2002.10
- RSI 1450.1
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+3.87%
200-day average slope, 3 months
+22.47%
50-day average slope, 1 month
-11.58%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
6.27 % per day
Volatility change
+63.97%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -0.53 (4) | -0.47 (3) | 0 (5) | — | -107 (4) |
| 2027 | -0.48 (4) | -0.45 (4) | 0 (5) | — | -112 (4) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of October 5, 2026.
Same sub-industry: 781 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AGEN | 5.6 | 4.9 | 289M USD | 2.4x | 69.3 % | 34.4 % | -11.7 % | 6.7x | -34.1 % | 44.8 % | ||
| 2 | SRZN | 5.5 | 4.3 | 298M USD | Not meaningful (loss) | -3042.9 % | 408.6 % | — | 2.2x | -11.8 % | 87.6 % | ||
| 3 | 6915 | 4.9 | 4.9 | 285M USD | — | — | 6.7 % | — | -0.7x | — | -7.8 % | ||
| 4 | PRLD | 4.7 | 3.5 | 291M USD | Not meaningful (loss) | -269.7 % | 73.4 % | -50.5 % | 2.0x | -11.4 % | 182.9 % | ||
| 5 | BNTC | 4.4 | N/A | 297M USD | Not meaningful (loss) | — | — | -33.1 % | 3.5x | -5.9 % | -46.2 % | ||
| 6 | NWBO | 3.5 | 4.0 | 281M USD | Not meaningful (loss) | -1736.4 % | 535.4 % | 275.6 % | -1.3x | -17.7 % | -25.0 % | ||
| 7 | IPSC | 3.4 | 1.5 | 310M USD | Not meaningful (loss) | — | -100.0 % | -41.9 % | — | -28.4 % | 207.6 % | ||
| 8 | XFOR | 3.2 | 3.0 | 298M USD | Not meaningful (loss) | -568.8 % | 346.3 % | -57.6 % | 1.5x | — | -4.4 % | ||
| 9 | A376900 | 2.7 | 3.0 | 279M USD | Not meaningful (loss) | -38.7 % | 36.6 % | -161.2 % | -7.1x | -6.0 % | -46.6 % |
